Gene Expression Profiling for Non-Invasive Graft Rejection Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring graft rejection in organ transplantation are invasive, unreliable, and lack non-invasive tools for predicting graft survival and differentiating between chronic graft injury and drug toxicity, leading to suboptimal treatment protocols.
Innovation Solution
The evaluation of gene expression in blood or biopsy samples using nucleic acid and protein assays to predict graft survival, identify deleterious conditions, and classify acute rejection severity, employing stringent hybridization conditions and gene-specific probes for accurate profiling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If biopsy procedures are used to monitor graft rejection, then diagnostic accuracy is improved, but patient comfort and procedural invasiveness deteriorate
Solution Approach 1:
The patent extracts the diagnostic function from invasive biopsy procedures by identifying and measuring specific gene expression markers (such as ICAM-1, HLA-DR, and other immune response genes) in peripheral blood samples. This allows the diagnostic capability to be separated from the invasive sampling method, enabling non-invasive monitoring while maintaining diagnostic accuracy for detecting acute cellular rejection and differentiating it from drug toxicity.
Solution Approach 2:
The patent introduces gene expression markers as intermediary indicators that mediate between the actual graft condition and the diagnostic measurement. Instead of directly examining graft tissue through biopsy, the method measures gene expression levels in blood cells that reflect the immune response to the graft, providing an indirect but accurate assessment of rejection status without invasive procedures.
2Reliability
If multiple protocol biopsies are performed to monitor progressive graft injury, then monitoring comprehensiveness is improved, but procedural complexity and patient burden increase
Solution Approach 1:
The patent creates a universal diagnostic method using gene expression profiling that can monitor multiple aspects of graft health through a single blood test. The same assay panel can detect acute cellular rejection, differentiate drug toxicity, and monitor progressive injury over time, replacing the need for multiple specialized biopsy procedures with one comprehensive non-invasive test.
Solution Approach 2:
The patent monitors graft health by measuring changes in gene expression parameters (mRNA levels of specific genes) in peripheral blood cells over time. This transforms the monitoring approach from examining structural changes in graft tissue through repeated biopsies to measuring dynamic molecular parameter changes in easily obtainable blood samples, simplifying the procedural while maintaining comprehensive monitoring.
3Measurement precision
If biopsy sampling and pathology analysis are used for differential diagnosis, then diagnostic capability is improved, but variability and confounding factors increase
Solution Approach 1:
The patent employs a feedback mechanism where gene expression levels of multiple markers are measured and compared against established patterns to determine the presence and severity of rejection. The method uses ratios and relative expression levels of paired genes (such as ICAM-1/ICAM-2, HLA-DR/HLA-A) to provide objective, quantifiable diagnostic criteria that reduce subjectivity and improve consistency in differential diagnosis between rejection and drug toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise prediction of graft survival, differentiation between chronic graft injury and drug toxicity, and personalized treatment protocols, improving transplant outcomes by providing a non-invasive means to assess graft function and rejection severity.
Implementation Method 1
employing stringent hybridization conditions and gene-specific probes for accurate profiling
Data Source
AI summary
Methods are provided for evaluating a subject for graft survival, e.g., in terms of predicting graft survival, identifying the presence of a deleterious graft condition, such as CAN and DT, identifying the severity and class of acute rejection, etc, in a subject are provided. In practicing the subject methods, the expression of at least one gene in a sample from the subject, e.g., a blood or biopsy sample, is assayed, e.g., at the nucleic acid and/or protein level, to evaluate the subject. Also provided are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.